Ondansetron Kabi

Ondansetron, the active ingredient in Ondansetron Kabi, is a serotonin 5-HT3 receptor antagonist presented as an injectable solution for intravenous use. It prevents nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Kabi belongs to the serotonin 5‑HT3 antagonist class and is used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: prevents or reduces nausea and vomiting associated with cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting that occur during or after radiation treatment. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures.

Common Side Effects: - Headache: mild to moderate pain often reported after administration. - Constipation: reduced bowel movements may occur. - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired. - Diarrhoea: loose stools in some patients. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm beyond QT issues. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic drugs. - Severe skin reactions: such as Stevens‑Johnson syndrome.

When using Ondansetron Kabi, consider the following precautions: - Renal impairment: assess kidney function and adjust dosing if required. - Hepatic impairment: use with caution in patients with liver disease. - Electrolyte abnormalities: monitor potassium and magnesium levels, especially in patients at risk for QT prolongation. - Cardiac risk: avoid in patients with known prolonged QT interval or concurrent QT‑prolonging drugs. - Pregnancy: safety not established; prescribe only if potential benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron Kabi may interact with several medicines. Monitor patients closely.

Major Interactions (Avoid): - Apomorphine: can cause severe hypotension and loss of consciousness. - Other QT‑prolonging agents: increased risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Cisplatin and other chemotherapeutics: may require dose adjustment of antiemetic therapy. - Ritonavir: can increase ondansetron plasma concentrations. - Aprepitant: may augment QT‑prolongation risk. - Serotonergic agents (SSRIs, MAO inhibitors): potential for serotonin syndrome.